A new analysis by ASCO shows substantial discordance between disclosures to ASCO and to Open Payments, confirming need for consistent, simpler financial disclosure systems in medicine.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Congress passed another continuing resolution (CR) on November 21 – the second CR since the start of the fiscal year (FY) on October 1. The CR provides flat funding for government agencies through December 20 to avoid a government shutdown and gives Congress more time to come to an agreement on a final FY 2020 appropriations package.
Short-term spending bills make it difficult for the National Institutes of Health (NIH) – as well as the institutions and scientists it supports – to effectively plan for research projects.
On December 11, from 3–4 PM (ET), the Oncology Nursing Society and ASCO will co-host a free webinar, “Offering Clinical Trials Can Make a Difference: Patient and Care Team Perspectives.”
ASCO’s Government Relations Committee Chair-elect, Carolyn Hendricks, MD, FASCO, spoke at a congressional briefing organized by the One Voice Against Cancer coalition about the importance of federal funding in making progress against cancer. ASCO also recently urged the leaders of the House and Senate Appropriations Committees to quickly enact a FY 2020 funding bill that includes robust, sustained funding for the NIH.
ASCO developed a Decision Aid to assist physician-investigators and research staff in determining whether an AE should be reported to the sponsor as an SAE and attributed to the investigational drug.
Researchers from around the country joined together for two days of learning and collaboration at ASCO’s headquarters in the greater DC metro area for the 2019 ASCO Research Community Forum (RCF) Annual Meeting. On September 22-23, 2019, experts in the field led timely presentations and discussions that coincided with the meeting’s theme of Working Smarter. Working Together.
On September 30, President Trump signed into law a Continuing Resolution (CR), which would provide flat funding for federal agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI), through November 21, 2019. ASCO encourages Congress to take action to include the highest increase possible in a full Fiscal Year (FY) 2020 funding package.
At the 2019 ASCO Advocacy Summit, ASCO members from 35 states held more than 160 Congressional meetings, urging Members of Congress to take action to advance policy priorities which improve patient access to cancer care, including clinical trials.
The National Cancer Institute (NCI) is sponsoring a quarterly webinar series honoring the legacy of Arti Hurria, MD, in improving the treatment of older adults with cancer. The first webinar titled, Perspectives on Cancer and Aging: Arti Hurria Memorial Webinar Series, will be held on October 7, 2019, from 1:00-2:00 pm ET.
ASCO today presented Representatives Ben Ray Luján (NM-3) and Gus Bilirakis (FL-12) with its annual Congressional Leadership Award in recognition of the lawmakers' exceptional, bipartisan commitment to supporting cancer research and treatment. The ASCO award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their cancer care teams.
Roughly one in five young adults uses e-cigarettes daily or recreationally, and nearly one in four believes the products are harmless and not addictive, according to findings from ASCO’s third annual National Cancer Opinion Survey. This comes after the Centers for Disease Control and Prevention (CDC) issued the results from its National Youth Tobacco Survey earlier this month, reporting that e-cigarette use among pre-teens and teens is on the rise. It is also despite warnings from the U.S. Surgeon General that e-cigarettes (also known as vapes) contain addictive and harmful or potentially harmful ingredients, including nicotine; lead and other heavy metals; and flavorants such as diacetyl, a chemical linked to serious lung disease. Amid public debate over banning flavored e-cigarettes, the ASCO survey also found that nearly three in 10 young adults think flavored e-cigarettes are less damaging to a person’s health than non-flavored ones. In addition, nearly seven in 10 Americans support raising the legal age to purchase e-cigarettes from 18 to 21.
During ASCO's upcoming Advocacy Summit, oncology care providers will urge lawmakers to improve clinical trial access, protect patients from unnecessary care delays, ensure acess to potentially lifesaving medications, and foster continued success of the MACRA program. ASCO members are invited to participate virtually through the ACT Network.
A new study in the Journal of Oncology Practice (JOP) comparing the use of subacute rehabilitation (SAR) instead of hospice referral since the availably of immunotherapy finds a growing number of people with cancer are being discharged to SAR, but approximately two-thirds do not receive further cancer therapy at any point. This research provides important insights for goals of care.
ASCO, through its Center for Research and Analytics (CENTRA®), has issued a request for research ideas from its members for projects that ASCO could conduct to develop generalizable new knowledge for the oncology community. Of particular need are research ideas that align with the priorities documented in Clinical Cancer Advances 2019: ASCO’s Annual Report on Progress Against Cancer and ASCO’s Strategic Plan or policy priorities. All ideas must be submitted by September 30 using a brief survey.
ASCO, CancerLinQ LLC and its technology collaborator Concerto HealthAI, and data from the practices that participate in the CancerLinQ® platform will be a part of the upcoming “8th Annual Blueprint for Breakthrough Forum—Validating Real-World Endpoints for an Evolving Regulatory Landscape” forum hosted by Friends of Cancer Research on September 18 in Washington, D.C.